Bristol Abilify “Approvable” For Bipolar Acute Mania
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb/Otsuka's Abilify (aripiprazole) is "approvable" for the treatment of acute mania in bipolar disorder, Bristol said during its first quarter earnings call April 28